Our Vision | Innovative Drug Development2018-03-09T13:57:02+00:00

Our Vision at Alzheon

We strive to bring transformational therapies to patients.

We are passionately dedicated to developing effective treatments for Alzheimer’s disease and other devastating neurodegenerative disorders.

We are applying innovation to drug development in neurodegeneration by capitalizing on scientific and clinical insights, so we can rapidly and efficiently  move towards new therapeutic solutions with substantially lower development risk.

We are committed to improving the lives of patients, their families and caregivers.

We aim to develop breakthrough therapies that can change the lives of patients with neurodegenerative disorders.

Our Approach

We are applying a targeted approach to Alzheimer’s.

The Right Patients:  APOE4/4 mild AD for confirmatory Phase 3 study

  • Homogeneous population of patients overexpressing Aβ pathology
  • Focus on the early stage of AD where Aβ oligomers a play key role in disease progression 

The Right Drug:
Improved ALZ-801 oral prodrug formulation

  • Consistent plasma levels provide for high brain penetration to inhibit Aβ oligomer formation
  • No vasogenic brain edema in tramiprosate clinical trials 

The Right Trial: 
FDA accepted trial design in APOE4/4 AD patients

  • Designed to confirm efficacy signals with same validated cognitive & functional measures
  • Favorable safety observed with tramiprosate in clinical trials involving more than 2,000 subjects
  • FDA agreed to the use of tramiprosate safety data for an NDA submission with ALZ-801
  • Fast Track designation granted by FDA for ALZ-801 AD program

For Patients and Caregivers

We are not yet enrolling patients in our Phase 3 clinical trial with ALZ-801.

Please check back as we will update our website when we are ready to start our clinical trial.